CG Oncology, Inc. Common stock

NASDAQ:CGON

Biotechnology

Healthcare
$80.00 +2.23%

+$1.35 today

Market cap
$7.15B
Beta
0.31
P/E (TTM)
-28.0
EPS (TTM)
-$2.21
52W Low $23.65High $75.50

Volume 1.79M

Average 1.08M

CGON Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

CG Oncology, Inc. Common stockNASDAQ: CGON

Short-term Debt · Q3 FY2026 · quarter ended Sep 2026

Short-term debt remains negative

Q3 FY2026 short-term debt was $1.13M, compared with $0 a year earlier.

Context

  • Short-term debt amounted to 0.1% of total assets at the end of Q3 FY2026, up 0.1 pp from a year earlier.
  • Short-term debt increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.13M— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoSep 2025
$0— since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Short-term Debt vs competitors

How CGON compares with its peers on the latest reported figures

  • CGON's Sep 2026 short-term debt of $1.13M is the 2nd highest of the 3 companies compared; the peer median is $958K.
  • Short-term debt amounts to 0.1% of total assets for CGON, versus a peer median of 0.4%.
CGON Competitors Peer median
Short-term Debt for CGON and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
URGNUroGen Pharma Ltd.Mar 2026$1.92M ——0.8%
CGONCG Oncology, Inc. Common stockSep 2026$1.13M ——0.1%
IBRXImmunityBio, Inc.Sep 2026$0 —-72.2%0.0%
Peer median (excluding CGON) $958K—-72.2%0.4%

Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents53.61M88.14M8.27M257.07M32.49M
Short-term Investments055.34M179.41M484.93M709.67M
Net Receivables2K303K92K781K688K
Inventory00001.57M
Other Current Assets4.8M3.42M6.36M11.43M15.07M
Total Current Assets58.41M147.21M194.12M754.21M759.48M
Property, Plant & Equipment (Net)200K506K491K493K19.57M
Goodwill000010.3M
Intangible Assets0000575K
Long-term Investments00000
Tax Assets00000
Other Non-current Assets85K33K4.69M94K1.68M
Total Non-current Assets285K539K5.18M587K32.12M
Total Assets58.69M147.75M199.3M754.8M791.59M
Account Payables1M985K3.24M6.52M5.71M
Short-term Debt2.94M8.97M569K00
Tax Payables00000
Deferred Revenue0000286K
Other Current Liabilities1.13M173K547K436K9.02M
Total Current Liabilities5.98M15.43M14.25M21.37M30.84M
Long-term Debt12.06M6.53M003M
Deferred Tax Liabilities0000307K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities351K352K13K01.74M
Total Non-current Liabilities12.47M7.14M257K52K8.15M
Total Liabilities18.44M22.57M14.51M21.42M38.99M
Common Stock3K008K8K
Retained Earnings(45.89M)(81.34M)(129.94M)(217.98M)(378.98M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity40.25M125.18M184.79M733.38M752.6M
Total Debt15.13M15.94M1.03M238K7.02M
Net Debt(38.48M)(72.2M)(7.24M)(256.83M)(25.47M)

CG Oncology, Inc. Common stock

NASDAQ:CGON

Intrinsic Alpha fair value

Locked

Current Price

$80.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.